Dedicated to quality and driven by excellence, we are committed to improving the lives of patients worldwide. We are steadfast in our goal to develop innovative cellular therapies that bring us closer to a cure.
From the very beginning, we’ve been focused on science. We came together
as a team of experts dedicated to quality, driven by excellence, and committed
to experimentation. Though we faced many challenges, we remain fearless in
our research and rigorous in our thinking, pushing ourselves to work harder.
At Legend Biotech, we have the opportunity to change the way treatments are developed across diseases and continents. Our goal is to reinvigorate treatment approaches in oncology and beyond.
The spark of hope is lit and we’re using that hope to ignite the future of cell therapy!
We welcome the opportunity to reinvigorate the treatment approaches in oncology and the future of cell therapy.
Today, our research is focused on continuous innovation in the field of cell therapy.
We are also future-focused on emerging technologies that can help address
some of the most chronic and life-threatening diseases.
Our goal is to reimagine healthcare and to deliver transformative treatments.
And at Legend Biotech, that’s what we’re doing every day.
Our driving force at Legend Biotech is sharing our passion for developing cutting-edge cell therapies with our colleagues and the healthcare community. We do that by being:
Efficient: We constantly look for inspiration inside
and outside the world of cell therapy.
Transparent: We work openly and collaboratively to establish trust and protect the relationships we’ve developed over time.
Passionate: We have an innate drive for scientific advancement in order to bring the power of cell therapies to patients.
Fearless: We focus on the importance of continuous learning and intellectual humility, using these attributes to advance to the next step.
Accountable: Be reliable and dependable; do what you say you will do. This idea is at the core of what we believe.
At Legend Biotech, we’re always looking for ways to reduce the enormous burden patients bear and the difficulties they face when dealing with their health, and our areas of research reflect that goal.
Our first product candidate, LCAR-B38M, is a B cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) cell therapy. The novel dual-epitope design of the BCMA targeting domain facilitates tight binding to BCMA, which is highly expressed on primary myeloma cells and plasma cells.1 Proof of concept has been achieved in an investigator-initiated, first-in-human study conducted in 74 patients with relapsed or refractory multiple myeloma in China. Legend Biotech has entered into a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize LCAR-B38M (JNJ-68284528) worldwide. We received clearance from China National Medical Products Administration in March 2018 for a phase II registration study in China, and Janssen received US Food and Drug Administration clearance for an Investigational New Drug Application in May 2018, and has since initiated a phase Ib/II study intended for registration in the US and EU.
We are actively building a robust pipeline in solid and liquid tumors, including gastric cancer, pancreatic cancer, ovarian cancer, and acute myeloid leukemia. In addition, we are looking to expand our research into infectious disease areas.
We are committed to developing impactful innovations. Our technology platforms include CAR-T, T-cell receptor (TCR), and allogeneic cell therapies.
To learn more about our clinical studies, visit https://clinicaltrials.gov
Reference: 1. Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048-60.